UNICYCIVE THERAPEUTICS INC (UNCY) Stock Price, Quote, News and Overview
NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD
UNCY Quote, Performance and Key Statistics
0.6342
+0.01 (+1.75%)
The current stock price of UNCY is 0.6342 USD. In the past month the price decreased by -0.22%. In the past year, price decreased by -38.43%.
UNCY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About UNCY
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 14 full-time employees. The company went IPO on 2021-06-17. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Company Info
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 14
Company Website: https://unicycive.com/
Investor Relations: https://unicycive.com/investors/
Phone: 16503840642
UNICYCIVE THERAPEUTICS INC / UNCY FAQ
What is the stock price of UNICYCIVE THERAPEUTICS INC today?
The current stock price of UNCY is 0.6342 USD. The price increased by 1.75% in the last trading session.
What is the ticker symbol for UNICYCIVE THERAPEUTICS INC stock?
The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.
On which exchange is UNCY stock listed?
UNCY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for UNICYCIVE THERAPEUTICS INC stock?
12 analysts have analysed UNCY and the average price target is 5.78 USD. This implies a price increase of 811.39% is expected in the next year compared to the current price of 0.6342. Check the UNICYCIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UNICYCIVE THERAPEUTICS INC worth?
UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 75.92M USD. This makes UNCY a Micro Cap stock.
How many employees does UNICYCIVE THERAPEUTICS INC have?
UNICYCIVE THERAPEUTICS INC (UNCY) currently has 14 employees.
What are the support and resistance levels for UNICYCIVE THERAPEUTICS INC (UNCY) stock?
UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 0.63 and a resistance level at 0.68. Check the full technical report for a detailed analysis of UNCY support and resistance levels.
Should I buy UNICYCIVE THERAPEUTICS INC (UNCY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of UNCY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of UNCY, evaluating the profitability, health, valuation and growth aspects
- UNICYCIVE THERAPEUTICS INC (UNCY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UNICYCIVE THERAPEUTICS INC (UNCY) Sales and EPS estimates to see what analysts future expectations are.
- UNICYCIVE THERAPEUTICS INC (UNCY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UNICYCIVE THERAPEUTICS INC (UNCY) Insider and Institutional Ownership to learn about the owners and their transactions.
- UNICYCIVE THERAPEUTICS INC (UNCY) Stock Chart to make your own analysis
- UNICYCIVE THERAPEUTICS INC (UNCY) Latest news and press-releases to stay up to date.
Does UNICYCIVE THERAPEUTICS INC (UNCY) stock pay dividends?
UNCY does not pay a dividend.
What is the Price/Earnings (PE) ratio of UNICYCIVE THERAPEUTICS INC (UNCY)?
UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
What is the Short Interest ratio of UNICYCIVE THERAPEUTICS INC (UNCY) stock?
The outstanding short interest for UNICYCIVE THERAPEUTICS INC (UNCY) is 1.44% of its float. Check the ownership tab for more information on the UNCY short interest.
UNCY Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is a bad performer in the overall market: 72.63% of all stocks are doing better.
UNCY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
UNCY Financial Highlights
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 33.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.44% | ||
| ROE | -509% | ||
| Debt/Equity | 0 |
UNCY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to UNCY. The Buy consensus is the average rating of analysts ratings from 12 analysts.